{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T10:20:47Z","timestamp":1795083647891,"version":"4.10.2"},"reference-count":19,"publisher":"BMJ","issue":"6","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Arch Dis Child Educ Pract Ed"],"accepted":{"date-parts":[[2026,3,4]]},"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1136\/archdischild-2025-330107","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T17:25:28Z","timestamp":1777051528000},"page":"266-270","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Delandistrogene moxeparvovec: gene therapy for Duchenne muscular dystrophy"],"prefix":"10.1136","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9235-2470","authenticated-orcid":false,"given":"Vivek","family":"Mundada","sequence":"first","affiliation":[{"name":"Paediatric Neurology, Aster DM Healthcare, Dubai, UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"key":"2026111902051464000_111.6.266.1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","article-title":"Duchenne muscular dystrophy","volume":"7","author":"Duan","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"2026111902051464000_111.6.266.2","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1002\/j.2040-4603.2015.tb00638.x","article-title":"The Dystrophin Complex: Structure, Function, and Implications for Therapy","volume":"5","author":"Gao","year":"2015","journal-title":"Compr Physiol"},{"key":"2026111902051464000_111.6.266.3","doi-asserted-by":"crossref","DOI":"10.3390\/medicina56090426","article-title":"Transition from Childhood to Adulthood in Patients with Duchenne Muscular Dystrophy","volume":"56","author":"Wasilewska","year":"2020","journal-title":"Medicina (Kaunas)"},{"key":"2026111902051464000_111.6.266.4","doi-asserted-by":"crossref","DOI":"10.1002\/ppul.71113","article-title":"Current Standards and Future Directions of Duchenne Muscular Dystrophy Respiratory Care: The PPMD Italy Meeting Report","volume":"60","author":"Racca","year":"2025","journal-title":"Pediatr Pulmonol"},{"key":"2026111902051464000_111.6.266.5","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01929-x"},{"key":"2026111902051464000_111.6.266.6","unstructured":"U.S. Food and Drug Administration . FDA recommends removal of voluntary hold on elevidys for ambulant patients. Silver Spring (MD): FDA; 2025. Available: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-recommends-removal-voluntary-hold-elevidys-ambulatory-patients"},{"key":"2026111902051464000_111.6.266.7","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2023.101147","article-title":"Development of capsid- and genome-modified optimized AAVrh74 vectors for muscle gene therapy","volume":"31","author":"Shoti","year":"2023","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2026111902051464000_111.6.266.8","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26178282","article-title":"AAV-Based Gene Therapy: Opportunities, Risks, and Scale-Up Strategies","volume":"26","author":"Moldavskii","year":"2025","journal-title":"Int J Mol Sci"},{"key":"2026111902051464000_111.6.266.9","unstructured":"U.S. Food and Drug Administration . FDA approves new safety warning and revised indication that limits use for elevidys following reports of fatal liver injury. Silver Spring (MD): FDA; 2025. Available: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-safety-warning-and-revised-indication-limits-use-elevidys-following-reports-fatal"},{"key":"2026111902051464000_111.6.266.10","doi-asserted-by":"crossref","unstructured":"Macedo AF , Logan J , Dai D , et al . Agreement and accuracy of ambulatory definitions in duchenne muscular dystrophy (dmd): a cross-sectional analysis. 29th Annual Congress of the World Muscle Society; 2024","DOI":"10.1016\/j.nmd.2024.07.128"},{"key":"2026111902051464000_111.6.266.11","unstructured":"European Medicines Agency . Elevidys: EPAR \u2013 medicine overview. 2025. Available: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/elevidys"},{"key":"2026111902051464000_111.6.266.12","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.pediatrneurol.2024.01.003","article-title":"Practical Considerations for Delandistrogene Moxeparvovec Gene Therapy in Patients With Duchenne Muscular Dystrophy","volume":"153","author":"Mendell","year":"2024","journal-title":"Pediatr Neurol"},{"key":"2026111902051464000_111.6.266.13","doi-asserted-by":"crossref","first-page":"687","DOI":"10.3233\/JND-230185","article-title":"Management of Select Adverse Events Following Delandistrogene Moxeparvovec Gene Therapy for Patients With Duchenne Muscular Dystrophy","volume":"11","author":"Zaidman","year":"2024","journal-title":"J Neuromuscul Dis"},{"key":"2026111902051464000_111.6.266.14","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ymthe.2025.10.007","article-title":"Real-world outcomes of delandistrogene moxeparvovec gene therapy: Motor outcomes and emerging safety concerns","volume":"34","author":"Keselman","year":"2026","journal-title":"Mol Ther"},{"key":"2026111902051464000_111.6.266.15","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2024.156"},{"key":"2026111902051464000_111.6.266.16","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41598-024-84077-w","article-title":"Immunologic investigations into transgene directed immune-mediated myositis following delandistrogene moxeparvovec gene therapy","volume":"15","author":"Potter","year":"2025","journal-title":"Sci Rep"},{"key":"2026111902051464000_111.6.266.17","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03304-z"},{"key":"2026111902051464000_111.6.266.18","doi-asserted-by":"crossref","first-page":"105587","DOI":"10.1016\/j.nmd.2025.105587","article-title":"424PDelandistrogene moxeparvovec micro-dystrophin expression and safety in 3\u20134-year-olds with Duchenne muscular dystrophy in ENDEAVOR and ENVOL studies","volume":"53","author":"McDonald","year":"2025","journal-title":"Neuromuscul Disord"},{"key":"2026111902051464000_111.6.266.19","unstructured":"Shieh P , Proud C , Diamond T , et al . Acute liver injury mitigation and management in patients with duchenne muscular dystrophy following administration of delandistrogene moxeparvovec: expert committee considerations. 30th Annual Congress of the World Muscle Society; Vienna, Austria, 2025"}],"container-title":["Archives of disease in childhood - Education &amp; practice edition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/archdischild-2025-330107","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T10:05:25Z","timestamp":1795082725000},"score":1,"resource":{"primary":{"URL":"https:\/\/ep.bmj.com\/lookup\/doi\/10.1136\/archdischild-2025-330107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":19,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,11,19]]},"published-print":{"date-parts":[[2026,12]]}},"alternative-id":["10.1136\/archdischild-2025-330107"],"URL":"https:\/\/doi.org\/10.1136\/archdischild-2025-330107","relation":{},"ISSN":["1743-0585","1743-0593"],"issn-type":[{"value":"1743-0585","type":"print"},{"value":"1743-0593","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]}}}